NC
MRNA icon

NZS Capital’s Moderna MRNA Stock Holding History

NZS Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-196,973
Closed -$13.2M – 62
2024
Q3 		$13.2M Buy
196,973
+5,599
+3% +$514K 0.51% 52
2024
Q2 		$22.7M Buy
191,374
+36,231
+23% +$4.58M 0.93% 38
2024
Q1 		$16.5M Buy
155,143
+29,771
+24% +$3M 0.69% 44
2023
Q4 		$12.5M Buy
125,372
+81,099
+183% +$6.82M 0.66% 45
2023
Q3 		$4.57M Sell
44,273
-77
-0.2% -$8.59K 0.25% 62
2023
Q2 		$5.39M Buy
44,350
+7,459
+20% +$995K 0.27% 61
2023
Q1 		$5.67M Buy
+36,891
New +$6.09M 0.3% 57

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

NZS Capital's MRNA Position: Q4 2024 in Review

NZS Capital sold out of Moderna (MRNA) in Q4 2024, closing a stake of 196,973 shares — an estimated $13.2M sold.

NZS Capital first reported a position in MRNA in Q1 2023 and held it in 7 quarters. The position peaked at $22.7M in Q2 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • NZS Capital reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • NZS Capital sold 196,973 Moderna shares in Q4 2024, an estimated $13.2M.
  • NZS Capital first reported a position in Moderna in Q1 2023 and held it in 7 quarters.
  • NZS Capital's Moderna position peaked at $22.7M in Q2 2024.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on NZS Capital's 13F filing for Q4 2024, filed 14 Feb 2025.